

March 22, 2024

BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

BSE Scrip Code: 506943 Stock Symbol: JBCHEPHARM

Dear Sir,

Sub.: Disclosure under Regulation 30 of the SEBI (Listing obligations and Disclosure Requirements), Regulations, 2015

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), this is to inform that the Company has received order from Assessment Unit, Income Tax Department.

The relevant information in the format prescribed by SEBI vide its circular no. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, is as under:

Name of the authority	Assessment Unit Income Tax Department
Nature and details of the action(s) taken, initiated or order(s) passed	Tax demand of Rs. 68.85 Lacs raised by making certain disallowances for AY 2022-23
Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	March 21, 2024
Details of the violation(s)/contravention(s) committed or alleged to be committed	Additions or Disallowances of expenses
Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	The Company has been advised that it has good case on merits. The Company will prefer an appeal before Commissioner (Appeals).



There is no impact on financial, operation or
other activities of the Company due to this
order.

We request you to take the above on record.

Thanking you,

Yours faithfully, For J.B. Chemicals & Pharmaceuticals Ltd.

Sandeep Phadnis Vice President – Secretarial & Company Secretary